Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05998408 · ClinicalTrials.gov registry record · Phase 1
JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
A Phase 1 study of Severe Aplastic Anemia and Single Lineage Cytopenias, T-LGL, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
- 1
- Study location
NCT05998408 is a Phase 1 study of Severe Aplastic Anemia and Single Lineage Cytopenias, T-LGL that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 145 participants, above the 118-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (23% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05998408, a Phase 1 study of Severe Aplastic Anemia and Single Lineage Cytopenias, T-LGL, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Immune bone marrow failure is a condition that occurs when a person s immune system attacks the cells of the bone marrow. This can lead to diseases including different types of anemias and blood cancers. Some of these diseases can be deadly. Better treatments are needed. Objective: To test a drug (ruxolitinib) in people with different types of immune bone marrow failure. Eligibility: Adults aged 18 and older with an immune bone marrow failure. Design: Participants will be screened. They will have a physical exam. They will give samples of blood and saliva. They will have a bone marrow biopsy: A large needle will be inserted into a small cut to remove a sample of the soft tissue inside the bone. Some participants may have a skin biopsy: A small piece of skin will be removed. Some may have a computed tomography (CT) scan: They will lie on a table that slides into a donut-shaped machine that uses X-rays to make pictures of the inside of the body. Ruxolitinib is a tablet taken by mouth. Participants will take the drug twice a day for up to 6 months. Participants will have blood tests every week while they are taking the drug. These tests can be done by the participant s own physician and the results sent to the researchers. Participants will have clinic visits after taking the drug for 3 months and 6 months and then after 1, 2, and 3 years. The blood tests and bone marrow biopsy will be repeated. Participants who improve while taking the drugs may go on to an extension phase of the study.
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2032-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05998408
The ClinicalTrials.gov registry entry for NCT05998408 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (23% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Severe Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT05998408 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05998408 about?
NCT05998408 is a clinical study titled "JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure". Background: Immune bone marrow failure is a condition that occurs when a person s immune system attacks the cells of the bone marrow. This can lead to diseases including different types of anemias and blood cancers. Some of these diseases can be deadly. Better treatments are needed. Objective: To...
What is the current status of trial NCT05998408?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2024-02-20. Estimated completion is 2032-06-03.
What conditions does trial NCT05998408 study?
This clinical trial studies the following conditions: Severe Aplastic Anemia, Single Lineage Cytopenias, T-LGL, Hypoplastic MDS.
What interventions are being tested in trial NCT05998408?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT05998408?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05998408 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RECRUITING · Phase 1
-
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
ACTIVE NOT RECRUITING · Phase 1
-
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Natural History of Acquired and Inherited Bone Marrow Failure Syndromes
RECRUITING
-
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.